Ionis Pharmaceuticals IONS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.06B+12.1% | $943.71M-2.4% | $966.96M+2.4% | $944.05M+31.6% | $717.25M+1.7% | ||
| $17.43M+9.6% | $15.91M+35.0% | $11.78M+12.0% | $10.52M-0.1% | $10.53M-6.1% | ||
| $1.04B+12.2% | $927.8M-2.9% | $955.17M+2.3% | $933.54M+32.1% | $706.72M+1.8% | ||
| 98.4%0.0pp | 98.3%-0.5pp | 98.8%-0.1pp | 98.9%+0.4pp | 98.5%+0.1pp | ||
| —— | $915.62M+0.4% | $912.1M+0.4% | $908.57M+0.4% | $905.05M+0.4% | ||
| $467.98M+18.8% | $393.87M+12.0% | $351.76M+11.1% | $316.59M+8.8% | $291.08M+8.8% | ||
| $1.41B+6.4% | $1.33B+6.5% | $1.25B+2.8% | $1.21B+1.8% | $1.19B+0.8% | ||
| -$352.25M+7.7% | -$381.69M-37.3% | -$278.05M-4.3% | -$266.52M+43.6% | -$472.43M+0.6% | ||
| -33.3%+7.2pp | -40.4%-11.7pp | -28.8%-0.5pp | -28.2%+37.6pp | -65.9%+1.5pp | ||
| $18.31M+6.1% | $17.26M+3.8% | $16.63M+0.3% | $16.57M-2.2% | $16.95M-0.3% | ||
| -$16.28M-6.0% | -$15.36M-1,347% | $1.23M+21.9% | $1.01M-33.4% | $1.52M+14.1% | ||
| -$325.09M+14.4% | -$379.6M-46.7% | -$258.72M+5.7% | -$274.43M+40.9% | -$464.16M-0.9% | ||
| $1.89M+5.7% | $1.79M+175% | -$2.38M+61.7% | -$6.22M-1.4% | -$6.13M+0.7% | ||
| -$326.98M+14.3% | -$381.39M-48.8% | -$256.34M+4.4% | -$268.22M+41.4% | -$458.03M-0.9% | ||
| -30.9%+9.5pp | -40.4%-13.9pp | -26.5%+1.9pp | -28.4%+35.4pp | -63.9%+0.5pp | ||
| -$2.07+15.2% | -$2.44-44.4% | -$1.69+8.2% | -$1.84+38.5% | -$2.99+1.6% | ||
| -$338.65M+8.3% | -$369.24M-38.4% | -$266.8M-4.6% | -$255.17M+44.6% | -$460.85M+0.5% | ||
| -32%+7.1pp | -39.1%-11.5pp | -27.6%-0.6pp | -27%+37.2pp | -64.3%+1.4pp | ||
| -$352.25M+7.7% | -$381.69M-37.3% | -$278.05M-4.3% | -$266.52M+43.6% | -$472.43M+0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ionis Pharmaceuticals's revenue?
- Ionis Pharmaceuticals (IONS) generated $1.1B in revenue over the trailing twelve months, up 47.5% year over year.
- Is Ionis Pharmaceuticals profitable?
- Ionis Pharmaceuticals is not currently profitable: it reported a net loss of $327.0M over the trailing twelve months, a -30.9% net margin.
- What are Ionis Pharmaceuticals's profit margins?
- Gross margin is 98.4% and operating margin is -33.3%, with a -30.9% net margin.
- What is Ionis Pharmaceuticals's earnings per share?
- Ionis Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.07.
- Where does Ionis Pharmaceuticals's income statement data come from?
- Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
